Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

BACKGROUND: HVTN 100 evaluated the safety and immunogenicity of an HIV subtype C pox-protein vaccine regimen, investigating a 12-month booster to extend vaccine-induced immune responses. METHODS AND FINDINGS: A phase 1–2 randomized double-blind placebo-controlled trial enrolled 252 participants (210...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:PLoS Med
Egile Nagusiak: Laher, Fatima, Moodie, Zoe, Cohen, Kristen W., Grunenberg, Nicole, Bekker, Linda-Gail, Allen, Mary, Frahm, Nicole, Yates, Nicole L., Morris, Lynn, Malahleha, Mookho, Mngadi, Kathryn, Daniels, Brodie, Innes, Craig, Saunders, Kevin, Grant, Shannon, Yu, Chenchen, Gilbert, Peter B., Phogat, Sanjay, DiazGranados, Carlos A., Koutsoukos, Marguerite, Van Der Meeren, Olivier, Bentley, Carter, Mkhize, Nonhlanhla N., Pensiero, Michael N., Mehra, Vijay L., Kublin, James G., Corey, Lawrence, Montefiori, David C., Gray, Glenda E., McElrath, M. Juliana, Tomaras, Georgia D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2020
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7039414/
https://ncbi.nlm.nih.gov/pubmed/32092060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.1003038
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak